House Dust Mix (1:10) Test & Treatment

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

Dust allergens, Quantity: 0.97 mL/mL (Equivalent: Dust allergens, Qty 97 mg/mL); Dust allergens, Quantity: 0.01 mL/mL (Equivalent: Dust allergens, Qty 1 mg/mL); Feathers, Quantity: 0.003 mL/mL (Equivalent: Feathers, Qty 0.3 mg/mL)

Pieejams no:

Stallergenes Australia Pty Ltd

Zāļu forma:

Extract, liquid

Kompozīcija:

Excipient Ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections

Ievadīšanas:

Subcutaneous

Vienības iepakojumā:

1 mL, 5 mL, 30 mL, 50 mL, 10 mL

Klase:

Medicine Registered

Receptes veids:

Not scheduled. Not considered by committee

Ārstēšanas norādes:

Indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Produktu pārskats:

Visual Identification: Clear liquid yellow to brown hue; Container Type: Multiple containers

Autorizācija statuss:

Registered

Autorizācija datums:

1991-11-01

Lietošanas instrukcija

DBL™ CARBOPLATIN
INJECTION
_carboplatin_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about DBL Carboplatin
Injection. It does not contain all the
available information. It does not
take the place of talking to your
doctor or pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking carboplatin
against the benefits they expect it
will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT DBL CARBOPLATIN
INJECTION IS USED FOR
This medicine is used to treat:
•
ovarian cancer
•
cancer of the testes
•
some types of lung cancer
•
cancer of the brain and/or spinal
cord
•
cancer of the head and neck
•
neuroblastoma (a cancer of the
nerves and adrenal glands)
•
a type of cancer called sarcoma.
Carboplatin belongs to a group of
medicines called antineoplastic or
cytotoxic medicines. You may also
hear of these being called
chemotherapy medicines. This
medicine is classified as a platinum-
complex cytotoxic.
It works by killing cancer cells and/
or stopping cancer cells from
growing and multiplying.
DBL Carboplatin Injection is often
used in combination with other
medicines to treat cancer.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY THIS MEDICINE
HAS BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed it
for another reason.
This medicine is not addictive.
This medicine is available only with
a doctor's prescription.
BEFORE YOU TAKE ARE
GIVEN DBL CARBOPLATIN
INJECTION
_WHEN YOU MUST NOT BE GIVEN_
_IT_
YOU SHOULD NOT BE GIVEN DBL
CARBOPLATIN INJECTION IF YOU HAVE
AN ALLERGY TO:
•
any medicine containing
carboplatin
•
other platinum-containing
compounds such as cisplatin or
oxaliplatin
•
mannitol
Some of the symptoms of an allergic
reaction may include:
•
shortness of breath
•
wheezing or difficulty breathing
•
swelling of the face, lips, tongue
or other parts of the body
•
ras

Produkta apraksts

Version: pfpcarpi11121
Superscedes: hhpcarpi10420
Page 1 of 13
AUSTRALIAN
PRODUCT
INFORMATION
–
DBL
™ CARBOPLATIN INJECTION (CARBOPLATIN)
1.
NAME OF THE MEDICINE
Carboplatin
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
DBL Carboplatin Injection is a sterile solution of carboplatin in
Water for Injections and is
presented in vials containing 5, 15, or 45 mL of 10 milligrams/mL
carboplatin.
Each mL of DBL Carboplatin Injection contains Carboplatin 10 mg.
3.
PHARMACEUTICAL FORM
Solution for injection.
DBL Carboplatin Injection is a clear, colourless or slightly yellow
solution free from
particulates. The solution does not contain any preservatives. The pH
of the injection ranges
between 4.0 to 7.0.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Carboplatin is indicated in the treatment of:
•
advanced stage ovarian cancer of epithelial origin
•
small cell lung carcinoma
•
carcinoma of the head and neck
•
carcinoma of the testis
•
paediatric cerebral tumours
•
soft tissue sarcoma
•
neuroblastoma.
4.2 DOSE AND METHOD OF ADMINISTRATION
DOSAGE
ADULT:
The recommended dose of carboplatin in previously untreated adults
with normal renal
function is 400 milligrams/m
2
given as a single intravenous infusion over 15 to 60 minutes.
Therapy should not be repeated until four weeks after the previous
carboplatin course.
It is recommended that according to clinical circumstances the initial
dosage may require
reduction by 20 to 25% in patients with risk factors such as
increasing age, previous
myelosuppressive therapy and poor performance status.
Version: pfpcarpi11121
Superscedes: hhpcarpi10420
Page 2 of 13
Dosage modification may be required when carboplatin is used in
combination with other
myelosuppressive drugs or radiation therapy, to minimise additive
myelosuppressive effects.
Determination of haematologic nadir by weekly blood counts during
initial courses is
recommended for future dosage adjustment and scheduling of
carboplatin.
DOSAGE ADJUSTMENT
_RENAL IMPAIRMENT _
In patients with initial impaired r